ReviewBMC pharmacology & toxicology2012
The potential for selective pharmacological therapies through biased receptor signaling.
Review in BMC pharmacology & toxicology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- 12(S)-HETE regulates the expression of IL-6 and IL-10 in cardiomyocytes through two distinct receptors, TXA2R and BLT2.Biochemistry and biophysics reports · 2026Article
- Targeting muscarinic receptors for treating schizophrenia.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- G protein-coupled receptors in prostate cancer: research progress and therapeutic targets.Frontiers in cell and developmental biology · 2025Review
- Biodistribution of the Bombesin Receptor-Targeted Radiopharmaceutical Precursor BBN/C1-C2 in a Prostate Cancer Model.Sovremennye tekhnologii v meditsine · 2025Article
- Characterization of behavioral changes in T-maze alternation from dopamine DPsychopharmacology · 2023Article
- Dose-Dependent Regulation on Prefrontal Neuronal Working Memory by Dopamine DFrontiers in neuroscience · 2022Article
- Receptor component protein, an endogenous allosteric modulator of family B G protein coupled receptors.Biochimica et biophysica acta. Biomembranes · 2020Article
- Structural Insight into G Protein-Coupled Receptor Signaling Efficacy and Bias between Gs and β-Arrestin.ACS pharmacology & translational science · 2019Article
- Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity.The international journal of neuropsychopharmacology · 2018Review
- Bioluminescence resonance energy transfer-based biosensors allow monitoring of ligand- and transducer-mediated GPCR conformational changes.Communications biology · 2018Article
- The evolution of regulators of G protein signalling proteins as drug targets - 20 years in the making: IUPHAR Review 21.British journal of pharmacology · 2017Review
- G Protein-Coupled Receptors in Cancer.International journal of molecular sciences · 2016Review
- Biased agonism: An emerging paradigm in GPCR drug discovery.Bioorganic & medicinal chemistry letters · 2016Review
- Differential CCR7 Targeting in Dendritic Cells by Three Naturally Occurring CC-Chemokines.Frontiers in immunology · 2016Article
- The mass action equation in pharmacology.British journal of clinical pharmacology · 2016Review
- Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR).The Journal of biological chemistry · 2014Article
- Divergent label-free cell phenotypic pharmacology of ligands at the overexpressed β₂-adrenergic receptors.Scientific reports · 2014Article
- Label-free drug discovery.Frontiers in pharmacology · 2014Review
- Biased and g protein-independent signaling of chemokine receptors.Frontiers in immunology · 2014Review
- Triphenylmethane dye activation of beta-arrestin.Biochemistry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery that not all agonists uniformly activate cellular signaling pathways (biased signaling) has greatly changed the drug discovery process for agonists and the strategy for treatment of disease with agonists. Technological advances have enabled complex receptor behaviors to be viewed independently and through these assays, the bias for an agonist can be quantified. It is predicted that therapeutic phenotypes will be linked, through translational studies, to quantified scales of bias to guide medicinal chemists in the drug discovery process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.